Skip to content

Clinical efficacy and changes in prefrontal cortex activity related to the treatment of medullary insufficiency in Parkinson's disease by the method of benefiting the essence and filling in the medulla oblongata

Clinical efficacy and changes in prefrontal cortex activity related to the treatment of medullary insufficiency in Parkinson's disease by the method of benefiting the essence and filling in the medulla oblongata

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000120
Enrollment
Unknown
Registered
2025-01-15
Start date
2024-10-30
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease(PD)

Interventions

Treatment group:Conventional anti-Parkinson drugs were used+Take Schisandrin recipe
Control group:Conventional anti-Parkinson drugs were used

Sponsors

Wenzhou Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: The general inclusion criteria were: 1. 20-80 years old; 2. taking stable medications within the past month; PD patients were included in the study if they also met the following criteria: 1. both met the above diagnostic criteria of traditional Chinese and western medicine; 2. According to TCM syndrome differentiation it belongs to the sea of marrow deficiency type; 3. Evaluation of patients with revised Hoehn-Yahr stage 1-3; 4. Dopamine replacement and other drugs were taken stably for more than 1 month; 5. voluntarily participated in the study and signed the informed consent; 6. those with correct understanding of the significance of this study and good compliance.

Exclusion criteria

Exclusion criteria: 1. Parkinsonism or Parkinsonism plus syndrome caused by drugs toxins infections cerebrovascular diseases and metabolic diseases; 2. complicated with other major diseases such as liver and kidney blood immune system; 3. Participating in other drug clinical trials at the same time; 4. those with severe mental illness who are unable to cooperate; 5. Unable to cooperate with fNIRS examination or have contraindications to fNIRS examination; 6. other patients who did not meet the diagnostic and inclusion criteria.

Design outcomes

Primary

MeasureTime frame
Unified Parkinson's Disease Rating Scale score;

Secondary

MeasureTime frame
Webster symptom Scale score;Changes in blood oxygen in the prefrontal lobe of the brain;Score of TCM syndrome integral scale;Parkinson's Cognitive function Rating Scale score;Montreal Cognitive Assessment scale score;

Countries

China

Contacts

Public ContactZhi Yinghao

Wenzhou Hospital of Traditional Chinese Medicine

43914515@qq.com13758472924

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026